Abbott Laboratories (ABT)
Abbott Stock Crash: Rebound Could Be Coming Fast
Abbott Laboratories TodayABTAbbott Laboratories$96.42 +0.95 (+1.00%) As of 10:45 AM Eastern This is a fair market value price provided by Massive. Learn more.52-Week Range$93.92▼$139.06Dividend Yield2.61%P/E Ratio25.86Price Target$121.00Add to Watchlist
Abbott Stock Falls Despite Q1 Earnings & Revenue Beat
ABT slips 4% despite Q1 beats as margin pressure, Nutrition weakness and lowered 2026 EPS guidance weigh on investor sentiment.
Abbott Laboratories (ABT) Q1 2026 Earnings Call Transcript
Abbott Laboratories (ABT) Q1 2026 Earnings Call Transcript
Weekly Jobless Claims Below Expectations
Weekly Jobless Claims Below Expectations.
Abbott Laboratories Cuts Outlook, Says Mild Flu Season Hurt Sales
Abbott Laboratories cut its full-year earnings outlook to account for a recent acquisition and said a weaker-than-expected flu season hurt its recent quarter.
Abbott Labs shares fall as earnings beat offset by Exact Sciences acquisition drag
Shares of Abbott Laboratories (NYSE:ABT) fell 3.2% on Thursday morning after the healthcare conglomerate marginally beat Wall Street estimates for quarterly profit and revenue, but flagged a hit to its 2026 earnings outlook from its recently completed cancer diagnostics acquisition. Investors weighed near-term earnings strength against dilution from the company's roughly $23 billion acquisition of Exact Sciences.
Abbott (ABT) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Abbott (ABT) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Abbott (ABT) Beats Q1 Earnings and Revenue Estimates
Abbott (ABT) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $1.14 per share. This compares to earnings of $1.09 per share a year ago.
Will Robust Medical Business Performance Fuel ABT's Q1 Earnings?
Abbott heads into Q1 earnings with solid Medical Devices and EPD growth, but Nutrition weakness and falling estimates cloud the outlook.
Unlocking Q1 Potential of Abbott (ABT): Exploring Wall Street Estimates for Key Metrics
Besides Wall Street's top-and-bottom-line estimates for Abbott (ABT), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2026.
Jury orders Abbott to pay $53 million in preterm infant formula trial, media report says
A jury in Chicago on Thursday said Abbott Laboratories must pay $53 million in compensatory damages to a group of families that had accused the company of failing to warn that its formula for premature infants can cause a potentially deadly bowel disease, according to the Chicago Tribune.
Abbott (ABT) Reports Next Week: Wall Street Expects Earnings Growth
Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
